NCT02833558

Brief Summary

Endoscopic submucosal dissection (ESD) is an endoscopic resection technique used to treat superficial neoplasia in the gastrointestinal tract. Bleeding is a commonly encountered problem during submucosal dissection and is usually managed with electrocautery. However, this does carry a risk of deep thermal injury and perforation. PuraStat® is a novel extracellular scaffold matrix of amino acids that forms a transparent adherent barrier when applied to a bleeding point. The aim of this trial is to study the use of PuraStat® in reducing the need for thermal haemostasis during ESD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
101

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 4, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 29, 2016

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 14, 2016

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 12, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 18, 2018

Completed
Last Updated

June 26, 2018

Status Verified

June 1, 2018

Enrollment Period

1.9 years

First QC Date

June 29, 2016

Last Update Submit

June 21, 2018

Conditions

Keywords

Endoscopy, GastrointestinalEndoscopic Submucosal DissectionBleeding

Outcome Measures

Primary Outcomes (1)

  • The number of times intraprocedural heat therapy is used to achieve haemostasis in ESD in both the PuraStat® and control arms of the study

    Measured during the ESD procedure

Secondary Outcomes (4)

  • The length of the procedure in the PuraStat® and control arm of the study

    Measured during the ESD procedure

  • The number of patients with delayed bleeding (bleeding within 28 days) in both the PuraStat® and control arm of the study

    28 days

  • Wound healing in the PuraStat® and control arm at 6 weeks post ESD

    6 weeks

  • Number of adverse events in the PuraStat® and control arm of the study

    14 months

Study Arms (2)

PuraStat®

EXPERIMENTAL

Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.

Device: PuraStat®

Standard Electrocautery

OTHER

Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD

Procedure: Electrocautery

Interventions

PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point

PuraStat®

Electrocautery (coagulation current) to stop bleeding during ESD

Standard Electrocautery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female, aged 18 years or above.
  • An ESD is attempted for clinical indications approved by MDT.
  • Oesophageal or colonic lesion 2-5cm in size
  • Participant is willing and able to give informed consent for participation in the study

You may not qualify if:

  • Known coagulopathy likely to affect risk of bleeding
  • Submucosal tumour
  • Anticoagulation or anti-platelet therapy (apart from single modality aspirin or clopidogrel) which cannot be stopped for clinical reasons
  • Patient preference

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Portsmputh Hospitals NHS Trust

Portsmouth, PO6 3LY, United Kingdom

Location

MeSH Terms

Conditions

Gastrointestinal HemorrhageHemorrhage

Interventions

Electrocoagulation

Condition Hierarchy (Ancestors)

Gastrointestinal DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

CauteryTherapeuticsAblation TechniquesSurgical Procedures, Operative

Study Officials

  • Pradeep Bhandari, MBBS, MD

    Portsmouth Hospitals NHS Trust

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 29, 2016

First Posted

July 14, 2016

Study Start

May 4, 2016

Primary Completion

April 12, 2018

Study Completion

May 18, 2018

Last Updated

June 26, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will share

Locations